Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
March 2015

A Two-Drug Combination for Weight Loss
The new medication Contrave, which combines the opioid-receptor antagonist naltrexone (ReVia and others) with the antidepressant and smoking cessation compound bupropion (Wellbutrin, Zyban, and others), has been approved as an adjunct to diet and increased exercise for certain overweight and obese patients.

Clozapine Trumps Polypharmacy
For patients with schizophrenia, clozapine (Clozaril and others) is associated with lower costs and reduced disease-specific emergency department use.

In Brief
Brain Activity in Men and Women Differs in Response to Cigarette Smoking; Patients with Anxiety Disorders Are at Greater Risk of Hypertension than the General Population

Lack of Cataracts with Quetiapine
Despite warnings about cataracts, quetiapine (Seroquel) actually appears to have a low risk of causing cataracts.

CME Reminder
March 31, 2015 is the deadline for returning your 2014 CME posttest to earn up to 12.0 hours of category 1 credit.

Download a Sample Issue of BTP

A following sample issue of Biological Therapies in Psychiatry is available in .pdf format. These files require Adobe Acrobat© Reader to view. (If you do not currently have the Acrobat Reader, click here to download).

Download a free sample pdf of BTP



One, two and three-year subscriptions are immediately available. Each subscription allows you full online access to current and recent issues, a searchable online database, downloadable audio files, and a printed newsletter that will be mailed to you monthly. You'll receive timely, accurate information at a very reasonable price. A one-year US subscription is only $86.00.


Subscribe